PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15158089-0	2004	Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.	Semaxinib	11-17	fms related receptor tyrosine kinase 3	Homo sapiens	75-79	
15158089-2	2004	SU5416 is a small molecule inhibitor of VEGF receptors, c-kit and FLT3 and therefore provides a novel opportunity to target both angiogenesis and proliferation in AML.	Semaxinib	0-6	fms related receptor tyrosine kinase 3	Homo sapiens	66-70	
15158089-4	2004	Since AML provides a unique platform to evaluate mechanism of action of small molecule inhibitors, investigation of the effect of SU5416 on FLT3 expression and phosphorylation in blood and bone marrow was an additional focus of this trial.	Semaxinib	130-136	fms related receptor tyrosine kinase 3	Homo sapiens	140-144	
15158089-5	2004	Phosphorylated FLT3 was detected by immunoprecipitation/Western analysis in peripheral blood samples from 17 of 22 patients, and seven exhibited strong inhibition of phosphorylation immediately following a 1h SU5416 infusion, demonstrating that SU5416 can modulate RTK phosphorylation in humans.	Semaxinib	209-215	fms related receptor tyrosine kinase 3	Homo sapiens	15-19	
15158089-5	2004	Phosphorylated FLT3 was detected by immunoprecipitation/Western analysis in peripheral blood samples from 17 of 22 patients, and seven exhibited strong inhibition of phosphorylation immediately following a 1h SU5416 infusion, demonstrating that SU5416 can modulate RTK phosphorylation in humans.	Semaxinib	245-251	fms related receptor tyrosine kinase 3	Homo sapiens	15-19	
15158089-6	2004	Although no clear correlation with clinical response was observed, analysis of patient plasma drug levels suggested that a threshold SU5416 concentration of 15 microM was associated with FLT3 inhibition.	Semaxinib	133-139	fms related receptor tyrosine kinase 3	Homo sapiens	187-191